Weill Medical College of Cornell University

• Home
• Overview
• Education
• Fellowships
• Research
• Faculty

Hepatitis

Clinical Studies of Viral Hepatitis. Marks, Glesby. Hepatitis C infection is the leading cause of end stage liver disease and need for liver transplantation in this country. Studies have shown that patients with HIV/HCV coinfection have an accelerated course of progression to cirrhosis and end stage liver disease compared to patients with HCV infection alone. Strategies for improving treatment outcomes are needed for this population. Current studies being conducted at Cornell focus on initial treatment of HCV infection as well as treatment of refractory disease. CCTU investigators are conducting an ACTG study utilizing the protease inhibitor, boceprevir, as part of HCV treatment (ACTG 5294). Completed studies include an epidemiologic investigation of risk factors for hepatic steatosis in HIV/HCV coinfection, a pilot study examining the safety and efficacy of treatment of acute HCV infection in HIV-infected patients, as well as additional clinical trials conducted with the ACTG. The Center for the Study of Hepatitis C, a multidisciplinary center involving Rockefeller University, Weill Cornell Medical College, and New York Presbyterian Hospital, provides additional opportunities for translational research, access to a serum and tissue bank, and collaboration with experts in the field of virology and hepatitis treatment (e.g. Drs. Ira Jacobson, Charlie Rice, Andrew Talal).

• Bussel JB, Marks KM. How effective is eltrombopag for the treatment of thrombocytopenia in patients with HCV infection? Nat Clin Pract Gastroenterol Hepatol 2008;5:424-25.
• Jackson C, Varon J, Ho A, Marks K, Talal A, Kreek M. Identification of substance use and dependence among patients with viral hepatitis. Dig Liver Dis 2010;42:650-56.
• Martinez AD, Dimova R, Marks KM, Beeder AB, Zeremski M, Kreek MJ, Talal AH. Integrated internist-addiction medicine-hepatology model for hepatitis C management for individuals on methadone maintenance. J Viral Hepat 2012;19(1):47-54.
• Talal AH, Liu R-C, Zeremski M, Dimova R, Dove L, Pearce D, Hassanein T, Doonguah L, Aboulafia D, Rodriguez J, Bonilla H, Galpin J, Aberg JA, Johnston B, Glesby MJ, Jacobson IM. Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/HCV patients receiving pegylated-interferon and ribavirin. J Acquir Immune Defic Syndr 2011;58:261- 68.
• Wan D, Marks KM, Yantiss R, Talal A. Autoimmune hepatitis in the HIV-infected patient: a therapeutic dilemma. AIDS Patient Care and STDs 2009;23:407-13.